About: Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine
Creator	Yan, Zhe Burkhard, Peter Jeffers, Scott Pimentel, Tais Hodges, Robert Holmes, Kathryn
Source	Medline; PMC
abstract	Severe acute respiratory syndrome (SARS) is an infectious disease caused by a novel coronavirus that cost nearly 800 lives. While there have been no recent outbreaks of the disease, the threat remains as SARS coronavirus (SARS-CoV) like strains still exist in animal reservoirs. Therefore, the development of a vaccine against SARS is in grave need. Here, we have designed and produced a prototypic SARS vaccine: a self-assembling polypeptide nanoparticle that repetitively displays a SARS B-cell epitope from the C-terminal heptad repeat of the virus’ spike protein. Biophysical analyses with circular dichroism, transmission electron microscopy and dynamic light scattering confirmed the computational design showing α-helcial nanoparticles with sizes of about 25 nm. Immunization experiments with no adjuvants were performed with BALB/c mice. An investigation of the binding properties of the elicited antibodies showed that they were highly conformation specific for the coiled-coil epitope because they specifically recognized the native trimeric conformation of C-terminal heptad repeat region. Consequently, the antisera exhibited neutralization activity in an in vitro infection inhibition assay. We conclude that these peptide nanoparticles represent a promising platform for vaccine design, in particular for diseases that are characterized by neutralizing epitopes with coiled-coil conformation such as SARS-CoV or other enveloped viruses.
has issue date	2009-01-01(xsd:dateTime)
bibo:doi	10.1111/j.1747-0285.2008.00746.x
bibo:pmid	19152635
has license	bronze-oa
sha1sum (hex)	d8158a9e3d6978dd4ccf81d3f4b641ecb91ec965
schema:url	https://doi.org/10.1111/j.1747-0285.2008.00746.x
resource representing a document's title	Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine
has PubMed Central identifier	PMC2756483
has PubMed identifier	19152635
schema:publication	Chemical Biology & Drug Design
resource representing a document's body	covid:d8158a9e3d6978dd4ccf81d3f4b641ecb91ec965#body_text
is schema:about of	named entity 'trimeric' named entity 'spike' named entity 'diseases' named entity 'Immunization' named entity 'Severe Acute Respiratory Syndrome' named entity 'vaccine' named entity 'sizes' named entity 'nanoparticles' named entity 'Here' named entity 'antibodies' named entity 'SARS coronavirus' named entity 'lives' named entity 'epitope' named entity 'conformation' named entity 'polypeptide' named entity 'conformation' named entity 'Vaccine' named entity 'Immunization' named entity 'self-assembling' named entity 'SARS' named entity 'epitope' named entity 'heptad repeat' named entity 'vaccine' named entity 'conformation' named entity 'conformation' named entity 'coiled-coil' named entity 'vaccine design' named entity 'Biophysical' named entity 'nanoparticles' named entity 'animal reservoirs' named entity 'antisera' named entity 'antibodies' named entity 'nanoparticle' named entity 'Vaccine' named entity 'Immunogens' named entity 'Nanoparticles' named entity 'Severe Acute Respiratory Syndrome' named entity 'Prototypic' named entity 'chloramphenicol' named entity 'dialysis' named entity 'biosafety level 3' named entity 'SARS' named entity 'Daltons' named entity 'protective antibodies' named entity 'nanoparticles' named entity 'recombinant' named entity 'SARS' named entity 'nanoparticle' named entity 'dynamic light scattering' named entity 'trimer' named entity 'peptide sequence' named entity 'SARS' named entity 'Raman' named entity 'alanines' named entity 'peptidic' named entity 'molecular weight' named entity 'SARS-CoV' named entity 'fusogenic' named entity 'MBP' named entity 'polypeptide' named entity 'protein design' named entity 'epitope' named entity 'antigen-presenting' named entity 'Eindhoven' named entity 'virion' named entity 'Sedimentation velocity' named entity 'icosahedral symmetry' named entity 'viral protein' named entity 'glycine' named entity 'heptad repeat' named entity 'nanoparticle' named entity 'B-cell' named entity 'peptide' named entity 'assay' named entity 'peptide chains' named entity 'monomers'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software